Skip to main content

Table 3 Studies of melatonin effects on CNS-related complications of diabetes

From: Melatonin: new insights on its therapeutic properties in diabetic complications

Type of study

Route of administration

Treatment duration

Target

Effect(s)

Refs.

In vivo dose (animal)

In vitro concentration (cell type)

10 mg/kg/day (male Wistar rats)

–

Intraperitoneal

2 weeks

Total antioxidant status, GSH, GPx, lipid peroxidation, IL-1β and IL-4 

Antioxidant effects

[128]

10 mg/kg/day (male Wistar rats)

–

Intraperitoneal

7 days

NCAM

GFAP

Prevented cognitive impairments

Antioxidant effects

[125]

10 mg/kg/day (Male Wistar rats)

–

Intraperitoneal

7 weeks

GSH, lipid peroxidation,

Improved memory and learning performance

[124]

10 mg/kg/day (male Wistar rats)

–

Intraperitoneal

6 weeks

GFAP

S100B

MDA

GSH

Reduced glial reactivity in the cerebellum, cortex, and hippocampus

Antioxidant effects

[126]

1 mg/kg/day (Male albino rattus norvegicus rats)

–

Intraperitoneal

4 weeks

GSH, SOD, CAT, lipid peroxidation

Anti-apoptotic effects

Antioxidant effects

[127]

10 mg/kg/day (male Wistar rats)

–

Intraperitoneal

2 weeks

NOS

Anti-apoptotic effects

Antioxidant effects

[104]

3, 10 mg/kg/day (male Sprague–Dawley rats)

–

Oral

2 weeks

GABA-glutamate homeostasisOxidative stress-PARP pathway

Improved neurochemical and neurobehavioral changes

[130]

10 mg/kg/day (male Wistar rats)

–

Intraperitoneal

4 weeks

S100B and GSH, and enhancement of AGE, lipid peroxidation

Ameliorated anxiety and depressive like-behaviors

[69]

10 mg/kg/day (male Wistar rats)

–

Intraperitoneal

4 weeks

GST, CAT, GPx, lipid peroxidation

Decreased anxiety and depression signs, and HbA1c levels

[139]